BACKGROUND: Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. METHODS: Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. RESULTS: EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p < .004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p < .013), and locoregional control (median, 104.4 vs 65.5 months; p < .043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p < .02) and locoregional control (median, 93.6 vs 64.5 months; p < .02). CONCLUSION: P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.
BACKGROUND: Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. METHODS: Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. RESULTS:EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p < .004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p < .013), and locoregional control (median, 104.4 vs 65.5 months; p < .043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p < .02) and locoregional control (median, 93.6 vs 64.5 months; p < .02). CONCLUSION:P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.
Authors: Kenneth W Yip; Wei Shi; Melania Pintilie; Joseph D Martin; Joseph D Mocanu; Derek Wong; Christine MacMillan; Pat Gullane; Brian O'Sullivan; Carlo Bastianutto; Fei-Fei Liu Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: C H Rassekh; P L Rady; I Arany; S K Tyring; S Knudsen; K H Calhoun; H Seikaly; B J Bailey Journal: Laryngoscope Date: 1998-03 Impact factor: 3.325
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2010-05 Impact factor: 3.147
Authors: Yitan Zhu; Abdallah S R Mohamed; Stephen Y Lai; Shengjie Yang; Aasheesh Kanwar; Lin Wei; Mona Kamal; Subhajit Sengupta; Hesham Elhalawani; Heath Skinner; Dennis S Mackin; Jay Shiao; Jay Messer; Andrew Wong; Yao Ding; Lifei Zhang; Laurence Court; Yuan Ji; Clifton D Fuller Journal: JCO Clin Cancer Inform Date: 2019-02